Traditional non-steroidal anti-inflammatory drugs (NSAIDs), such as sulindac, inhibit COX-2 expression resulting in reduced Wnt-signaling by induced β-catenin degradation, as has been shown in colon cancer [27]. Here, PTGS2 is linked to colonic neoplasm.